Andrew D. Zelenetz, MD, PhD

Articles

Dr. Zelenetz on Progress Made in MCL Treatment

May 15th 2020

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Dr. Zelenetz on Progress Made in MCL Treatment

May 14th 2020

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Dr. Zelenetz on Zanubrutinib Research in MCL

October 18th 2019

Andrew D. Zelenetz, MD, PhD, discusses research with zanubrutinib in mantle cell lymphoma.

Dr. Zelenetz on Current Treatment Options for MCL

September 25th 2019

Andrew D. Zelenetz, MD, PhD, discusses approved treatment options for patients with mantle cell lymphoma, as well as treatments coming down the pipeline.

Dr. Zelenetz on Anticipated Research in MCL

September 18th 2019

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses anticipated research in mantle cell lymphoma (MCL).

Dr. Zelenetz on Nivolumab Plus Ibrutinib in Patients With CLL

April 26th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Dr. Zelenetz on Potential of Acalabrutinib and BGB-3111 in CLL

April 19th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses the potential with acalabrutinib and BGB-3111 for the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Zelenetz on Treatment for Patients With CLL Who Fail on Ibrutinib or Idelalisib

January 4th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia who fail on ibrutinib or idelalisib.

Dr. Zelenetz on the Role of Biosimilars in Cancer Care

March 31st 2016

Andrew D. Zelenetz, MD, PhD, medical director, Quality Informatics, Memorial Sloan Kettering Cancer Center, discusses the role of biosimilars in cancer care. Zelenetz spoke about this topic at the 2016 NCCN Annual Conference.

Dr. Zelenetz on Treating Hematologic Malignancies

March 6th 2013

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancies.

Dr. Zelenetz on the Impact of Rituximab in Lymphoma

January 14th 2013

Andrew D. Zelenetz, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

Dr. Zelenetz Highlights Studies From the 2012 ASH Meeting

December 11th 2012

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the trials investigating ABT-199 and ibrutinib that were presented at the 2012 American Society of Hematology (ASH) Meeting.

Dr. Zelenetz Previews the 2012 ASH Annual Meeting

September 26th 2012

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, previews several trials that will likely be presented at the 54th annual ASH meeting.

Dr. Zelenetz Discusses Treatment Options for DLBCL

April 26th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Treatment Options for DLBCL

Dr. Zelenetz Discusses DLBCL Targeted Therapies

March 29th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Dr. Zelenetz Discusses the Winter Hematology Meeting

January 5th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses the Winter Hematology Meeting

Dr. Zelenetz Discusses Brentuximab Vedotin

December 22nd 2011

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Brentuximab Vedotin

Dr. Zelenetz Discusses the Chemo Delivery Process

December 21st 2011

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses the Chemotherapy Delivery Process